Call2Recycle Marks Record-Breaking Year in Battery Recycling across Canada

Over 6.8 million kilograms of batteries collected & recycled in 2024 Call2Recycle, Canada's leading battery collection and recycling organization, is excited to mark National Battery Day by announcing that Canadians recycled over 6.8 million kilograms of used batteries in 2024, through its Recycle Your Batteries, Canada!program – representing a 17% increase from the previous year, […]

REMINDER / GDI INTEGRATED FACILITY SERVICES INC.: FINANCIAL RESULTS FOR THE FOURTH QUARTER ENDED DECEMBER 31, 2024

RELEASE DATE AND CONFERENCE CALL GDI Integrated Facility Services Inc. (“GDI”) (TSX: GDI) will release its financial results for the fourth quarter ended December 31,2024, on Tuesday, March 4, 2025, following market close. GDI will hold a conference call on Wednesday, March 5, 2025, at 9:00 a.m. (Eastern Time) to discuss its financial and operating

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

(NASDAQ:PPBT),(TASE:PPBT.TA), NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux) The study is conducted in collaboration with the University of Colorado Anschutz Medical Campus and is led by Dr. Antonio Jimeno, Professor and Director

H&E Equipment Services, Inc. Receives Superior Proposal from Herc Holdings Inc.

(NASDAQ:HEES),(NYSE:HRI),(NYSE:URI), BATON ROUGE, La., Feb. 18, 2025 (GLOBE NEWSWIRE) — H&E Equipment Services, Inc. d/b/a H&E Rentals (NASDAQ: HEES) (“H&E”) today announced that it has determined that a definitive offer from Herc Holdings Inc. (NYSE: HRI) (“Herc”) to acquire all of the outstanding shares of H&E common stock for a combination of cash and Herc

Mobilicom’s SkyHopper PRO & PRO Lite Added to the Defense Innovation Unit’s Blue UAS Framework

(NASDAQ:MOB),(NASDAQ:MOBBW),(AUST:MOB.AX), Winning the Blue UAS Refresh allowed Mobilicom's datalinks to undergo NDAA and cyber security verification for addition to the Blue UAS Framework. This allows procurement and integration into all U.S. Blue UAS List platforms Mobilicom selected to be on a prestigious shortlist for UAS radios following rigorous review Becoming part of the Blue UAS

Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite’s Namodenoson

(NYSE MKT:CANF),(TASE:CFBI),(TASE:CANF.TA), Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030 Ramat Gan, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced a significant

Beamr Strengthens Partnership with AWS by Joining AWS ISV Accelerate: a Global Co-Sell Program

(NASDAQ:BMR), “Our partnership with AWS is strategic to Beamr's growth, and joining the ISV Accelerate program represents a significant milestone in our cloud strategy,” said Beamr CEO, Sharon Carmel Herzliya Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) — Beamr Imaging Ltd. (NASDAQ: BMR), a leader in video optimization technology and solutions, today announced it has joined

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 Receptor Agonists

(NASDAQ:ELAB), Northstrive Biosciences Inc. (“Northstrive Biosciences”) has submitted a pre-Investigational New Drug (“pre-IND”) meeting request to the U.S. Food and Drug Administration (“FDA”) for EL-22, a novel myostatin asset aimed at preserving muscle while on weight loss treatments. A pre-IND meeting with the FDA is expected in Q2 2025 to discuss nonclinical studies and Northstrive

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

(NasdaqGM:AXSM), Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year growth Auvelity(R) 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively, representing 89% and 124% year-over-year growth Sunosi(R) 4Q and full year 2024 net product revenue of

LEEF Brands Signs Binding Letter of Intent to Acquire a Tier 1 Processing License in New York, Paving the Way to Enter the $1.5B Cannabis Market in 2025

(CNSX:LEEF.CN),(OTC US:LEEEF),(Other OTC:LEEEF),(CNSX:LEEF), VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) — LEEF Brands Inc. (CSE: LEEF) (OTCQB: LEEEF) (“LEEF Brands” or the “Company”), a leading California cannabis extraction company, today announced the signing of a binding Letter of Intent to acquire a Type 1 processing license, marking its strategic entry into New York's rapidly

Scroll to Top